Robert Berman, M.D.

Robert Berman, M.D.

Senior Clinical Advisor

Robert is Senior Clinical Advisor to Syndeio Biosciences. He is also Head of the Scientific Advisory Board and Senior Medical Advisory at Freedom Biosciences. His research career started in academia at Yale, where he studied the mechanism of action of antidepressants and novel treatments for psychiatric disorders, including exploiting the value of already-approved agents such as ketamine and pindolol. For over 20 years he has worked within the industry, first at Pfizer and then Bristol-Myers Squibb, in clinical development roles, including leading the program for aripiprazole in depression, for which he developed novel clinical trial designs that achieved three out of three highly statistically significant trials. In 2013, he co-founded Biohaven Pharmaceuticals (NYSE:BHVN) and was Chief Medical Officer until 2019.

Robert completed his undergraduate degree at Yale University in molecular biophysics and biochemistry, and received his medical degree from the Mount Sinai School of Medicine in 1990. He is currently an Adjunct Professor of Psychiatry at the Yale University School of Medicine and has over 70 peer-reviewed publications.